Albireo initiates phase II trial for cholestatic liver disease compound
TeaserAlbireo announced Thursday that it is beginning a phase II trial with the company’s lead compound for cholestatic liver disease and NASH, A4250. Read More »
TeaserAlbireo announced Thursday that it is beginning a phase II trial with the company’s lead compound for cholestatic liver disease and NASH, A4250. Read More »
TeaserHelsinn Healthcare S.A. Read More »
An American Pharmacists Association (APhA) official released a statement on Thursday, stressing the important role of childhood and booster vaccinations in the protection of individual lives and overall public health. Read More »
Pharmacy Today released the findings of its annual survey on over-the-counter (OTC) products on Thursday, conducted by the American Pharmacists Association, revealing which OTC products were recommended most frequently by U.S. pharmacists during July 2014. Read More »
Acura Pharmaceuticals said on Thursday that it has launched NEXAFEDÂ Sinus Pressure + Pain, a pseudoephedrine, methamphetamine-resistant, immediate-release tablet that relieves congestion, pain and fever from colds and allergies. Read More »
The U.S. Food and Drug Administration said on Tuesday that is has approved the use of Pfizer's palbociclib oral capsules, in combination with letrozole, to treat advanced breast cancer. Read More »
TeaserUpsher-Smith Laboratories, Inc. announced Monday that a new saving and support program is available for patients who have been prescribed Qudexy XR extended-release capsules. Read More »
Genentech, a member of the Roche group, said on Friday that the U.S. Food and Drug Administration (FDA) approved Lucentis, the first eye medicine sanctioned to treat diabetic retinopathy (DR) with diabetic macular edema (DME). Read More »
Alkermes, PLC, said on Monday that it has produced positive results from a phase one, randomized, double-blind clinical study of ALKS 8700, an oral monomethyl fumarate (MMF) molecule in development as a multiple sclerosis (MS) treatment. Read More »
Daiichi Sankyo Company, Ltd. announced on Monday that SAVAYSA, a once-daily, oral, selective factor Xa-inhibitor, is now available in pharmacies within the United States. Read More »
Novo Nordisk and Karolinska Institutet signed a collaboration agreement on Monday Read More »
TeaserMylan Inc. confirmed Monday that it and its subsidiary, Mylan Pharmaceuticals, have been sued by Onyx Pharmaceuticals, Bayer Healthcare LLC and Bayer Healthcare Pharmaceuticals Inc. in connection to an application to make a generic form of NEXAVAR. Read More »
The Generic Pharmaceutical Association (GPhA) announced its 2015 executive committee and board of directors on Monday. Read More »
The CVS Health Foundation said last week that it has formed a partnership with the Campaign for Tobacco-Free Kids (CTFK) through the “Making the Next Generation Tobacco-Free” program, which will provide grants to organizations implementing health strategies to reduce youth tobacco use and exposure to secondhand smoke. Read More »
Findings of an updated Visante study prepared for the Pharmaceutical Care Management association revealed proposed Maximum Allowable Cost (MAC) restriction could increase the costs of affected generic drugs by up to 56 percent. Read More »
Rite Aid and Envision Pharmaceutical Services (EnvisionRx) said on Wednesday that they have reached a final agreement in which Rite Aid will purchase EnvisionRX, a transaction valued at approximately $2 billion. Read More »
The Senior Care Pharmacy Coalition (SCPC) on Wednesday endorsed the MAC Transparency Act, a new bipartisan bill introduced by U.S. Read More »
Catamaran Corp. will launch a new clinical outcomes-based program for hepatitis C. Read More »
The Any Willing Pharmacy bill (HR 793), supported by the drugstore lobby, would limit access to lower-cost, preferred pharmacies under Medicare Part D and increase Medicare spending by $21 billion in the next 10 years, the Moran Company's research said. Read More »
Amgen said on Wednesday that its Biologics License Application (BLA) for talimogene laherparepvec will be reviewed by the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) and the Cellular, Tissue and Gene Therapies Advisory Committee. Read More »